The Clinical Genomics Workspace

Velsera's Clinical Genomics Workspace (CGW) is an all-in-one analysis and reporting tool for clinical next-generation sequencing (NGS) data, enhancing the quality and efficiency of patient care delivery. It leverages our industry-leading knowledgebase to keep medical recommendations current and offers comprehensive clinical reporting so your team can focus on helping patients.

Save Time: Streamlined Evidence Review

The platform's clinical evidence review capabilities speed up report sign-out times by remembering your previous reporting decisions, automatically classifying variants, and guiding your review of variants of uncertain significance (VUS). Further, with visualized variant quality review, you can tailor filters to clearly distinguish between variants that automatically pass your criteria and those that require manual review.

End-to-End Solution

Cover the full continuum from data transfer, case accessioning, variant calling, annotation, interpretation, report, sign-out, and result integration in one single platform.

Updated Diagnostic Knowledge

Reduce cost, time and risk by leveraging our data sharing network and professional curation that make up our best-in-class knowledgebase.

Flexibility

With support for all instruments, assays, and disease indications, configurable report templates distinguish labs and assay vendors from the competition by allowing customization to meet customer needs.

Built on Expertise & Trust

Years of experience guiding hundreds of somatic and germline customers, and appreciation for the complexities and unique customer needs in the daily work of molecular diagnostic labs.



TruSight™ Oncology 500

6 Cityplace Dr. Suite 550 Creve
Coeur, MO 63141
+1 314-628-0035

YOUR LOGO HERE

Patient Information
Name: Firstname Lastname
Date of Birth: 7-Jan-1960
MRN#: 12345
Disease: Non-small cell lung cancer

Order Details
Ordering Physician: Dr. Smith
Specimen Type: Formalin-fixed paraffin-embedded tissue specimen
Date Collected: 1-Feb-2024
Accession#: Lotus_Test_CSRT_NSCLC5

Clinical Implications

TIER	VARIANT DETECTED (GENE/ SYNTAX)	CLINICAL IMPACT		SELECT CLINICAL TRIALS
IA	MET Altered transcript in *MET*	**May benefit from:**	Tepotinib , Atezolizumab , Capmatinib , Cemiplimab-rwlc , Crizotinib , Durvalumab + Tremelimumab-actl , Ipilimumab + Nivolumab , Pembrolizumab	7
		In Tumor Type:	Non-small cell lung cancer	
		May benefit from:	Atezolizumab + Bevacizumab , Bevacizumab	
		In Tumor Type:	Nonsquamous non-small cell lung cancer	
		Unfavorable prognosis in:	Adenocarcinoma of lung Sarcomatoid carcinoma of lung	
IIC	EML4, ALK *EML4-ALK* fusion transcript + KRAS p.G12C	**Not likely to benefit from:**	Crizotinib	0
		In Tumor Type:	Adenocarcinoma of lung, Large cell carcinoma of lung	
IB	EML4, ALK *EML4-ALK* fusion transcript + TP53 p.R248W	**Not likely to benefit from:**	Alectinib , Brigatinib , Ceritinib , Crizotinib	0
		In Tumor Type:	Non-small cell lung cancer	
		Unfavorable prognosis in:	Non-small cell lung cancer	
IB	TP53 p.R248W	**May benefit from:**	Nivolumab	1
		In Tumor Type:	Non-small cell lung cancer	

Clinical Report Example (TSO 500)

CGW simplifies drafting, customizing, and sign-out of clinical reports for diagnostic labs. Customize report content available to your physician customers for rapid comprehension and to facilitate treatment selection.

People, Not Just Software

Our team of experts are here to help - whether you are launching your first NGS program or looking to scale and grow your existing operation. Board-certified medical directors oversee variant analyst services & sign out clinical reports. We can collaborate for laboratory design, gap analysis, audit readiness, clinical validation, health IT integration, reimbursement, and compliance.

SCHRAFFT'S CITY CENTER, 529 MAIN ST
SUITE 6610, CHARLESTOWN, MA 02129

A Look Inside the Platform

With a user-friendly interface, CGW enables your team to focus on delivering the best patient care possible. The platform is designed to save your team time without compromising on clinical quality.



Organize and view variants by type, each with its appropriate quality parameters

Graphical filtering for intuitive representation of your configured filters

Perform ad-hoc filtering and add display columns

Variant Quality Review, with Visual Filters

Variant quality is reviewed using pre-designed filters that align with your assay's analytic validation performance characteristics. The platform offers a guided workflow to automate most variant quality triage and draws your attention to the most challenging variants that may hold clinical significance.



Triage of Variants

In this step, variants that lack clear clinical significance are presented for further review, and available evidence is displayed for rapid assessment of variants of uncertain significance (VUS). CGW's guided workflow ensures that the appropriate variants are included in the final report.



Detailed Clinical Evidence Review and Interpretation

Clinical evidence from the knowledgebase, including approved and emerging therapies, prognostic and diagnostic associations, and clinical trials, can be selected for reporting. Interpretation text is automatically drafted based on your selected associations. View the PDF report live in parallel as your finalize the content.

UPDATED APRIL 2024
SCHRAFFT'S CITY CENTER, 529 MAIN ST
SUITE 6610, CHARLESTOWN, MA 02129